Search

Author/Creator Blauvelt, A.

1. 012 Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis. (1st February 2018)

Authors:
Ryan, C.; Menter, A.; Guenther, L.; Blauvelt, A.; Bissonnette, R.; Yang, F.E.; Potts Bleakman, A.
Journal:
Journal of sexual medicine
Issue:
Volume 15(2018)Supplement 1
Page Start:
S6
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (15th January 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.
Other Names:
Vender Ronald investigator.; Lomaga Mark A. investigator.; Delorme Isabelle investigator.; Hong Chih‐Ho investigator.; Langley Richard L. investigator.; Albrecht Lorne investigator.; Guenther Lyn investigator.; Maari Catherine investigator.; Papp Kim investigator.; Singh Ohson Kamal K. investigat...
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. (1st June 2021)

Authors:
Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 6(2021)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. (1st June 2021)

Authors:
Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 6(2021)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. (25th October 2020)

Authors:
Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 6(2021)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis. (1st August 2016)

Authors:
Papp, K.A.; Reich, K.; Paul, C.; Blauvelt, A.; Baran, W.; Bolduc, C.; Toth, D.; Langley, R.G.; Cather, J.; Gottlieb, A.B.; Thaçi, D.; Krueger, J.G.; Russell, C.B.; Milmont, C.E.; Li, J.; Klekotka, P.A.; Kricorian, G.; Nirula, A.
Journal:
British journal of dermatology
Issue:
Volume 175:Number 2(2016)
Page Start:
273
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis4. (23rd June 2016)

Authors:
Papp, K.A.; Reich, K.; Paul, C.; Blauvelt, A.; Baran, W.; Bolduc, C.; Toth, D.; Langley, R.G.; Cather, J.; Gottlieb, A.B.; Thaçi, D.; Krueger, J.G.; Russell, C.B.; Milmont, C.E.; Li, J.; Klekotka, P.A.; Kricorian, G.; Nirula, A.
Journal:
British journal of dermatology
Issue:
Volume 175:Number 2(2016)
Page Start:
273
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis. (1st June 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
e193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗